|
1
|
Abraham P and Acharya S: Current and
emerging treatment options for Graves' hyperthyroidism. Ther Clin
Risk Manag. 6:29–40. 2010.PubMed/NCBI
|
|
2
|
Ayadi H, Hadj Kacem H, Rebai A and Farid
NR: The genetics of autoimmune thyroid disease. Trends Endocrinol
Metab. 15:234–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mavragani CP, Patronas N, Dalakas M and
Moutsopoulos HM: Ill-defined neurological syndromes with autoimmune
background: A diagnostic challenge. J Rheumatol. 34:341–345.
2007.PubMed/NCBI
|
|
4
|
Afeltra A, Vadacca M, Conti L, Galluzzo S,
Mitterhofer AP, Ferri GM, Del Porto F, Caccavo D, Gandolfo GM and
Amoroso A: Thrombosis in systemic lupus erythematosus: Congenital
and acquired risk factors. Arthritis Rheum. 53:452–459. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petri M, Roubenoff R, Dallal GE, Nadeau
MR, Selhub J and Rosenberg IH: Plasma homocysteine as a risk factor
for atherothrombotic events in systemic lupus erythematosus.
Lancet. 348:1120–1124. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Foffa I, Festa PL, Ait-Ali L, Mazzone A,
Bevilacqua S and Andreassi MG: Ascending aortic aneurysm in a
patient with bicuspid aortic valve, positive history of systemic
autoimmune diseases and common genetic factors: A case report.
Cardiovasc Ultrasound. 7:342009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mao R, Fan Y, Zuo L, Geng D, Meng F, Zhu
J, Li Q, Qiao H, Jin Y, Bai J and Fu S: Association study between
methylenetetrahydrofolate reductase gene polymorphisms and Graves'
disease. Cell Biochem Funct. 28:585–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weetman AP: Graves' disease. N Engl J Med.
343:1236–1248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gianoukakis AG and Smith TJ: Recent
insights into the pathogenesis and management of thyroid-associated
ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 15:446–452.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anvari M, Khalilzadeh O, Esteghamati A,
Esfahani SA, Rashidi A, Etemadi A, Mahmoudi M and Amirzargar AA:
Genetic susceptibility to Graves' ophthalmopathy: The role of
polymorphisms in proinflammatory cytokine genes. Eye (Lond).
24:1058–1063. 2010. View Article : Google Scholar
|
|
11
|
Werner SC: Modification of the
classification of the eye changes of Graves' disease:
Recommendations of the Ad Hoc Committee of the American Thyroid
Association. J Clin Endocrinol Metab. 44:203–204. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gianoukakis AG, Khadavi N and Smith TJ:
Cytokines, Graves' disease, and thyroid-associated ophthalmopathy.
Thyroid. 18:953–958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuriyan AE, Phipps RP and Feldon SE: The
eye and thyroid disease. Curr Opin Ophthalmol. 19:499–506. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khoo TK and Bahn RS: Pathogenesis of
Graves' ophthalmopathy: The role of autoantibodies. Thyroid.
17:1013–1018. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fatourechi V, Garrity JA, Bartley GB,
Bergstralh EJ, DeSanto LW and Gorman CA: Graves ophthalmopathy.
Results of transantral orbital decompression performed primarily
for cosmetic indications. Ophthalmology. 101:938–942. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esteghamati A, Khalilzadeh O, Mobarra Z,
Anvari M, Tahvildari M, Amiri HM, Rashidi A, Solgi G, Parivar K,
Nikbin B and Amirzargar A: Association of CTLA-4 gene polymorphism
with Graves' disease and ophthalmopathy in Iranian patients. Eur J
Intern Med. 20:424–428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yin X, Latif R, Bahn R, Tomer Y and Davies
TF: Influence of the TSH receptor gene on susceptibility to Graves'
disease and Graves' ophthalmopathy. Thyroid. 18:1201–1206. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Villanueva R, Inzerillo AM, Tomer Y,
Barbesino G, Meltzer M, Concepcion ES, Greenberg DA, MacLaren N,
Sun ZS, Zhang DM, et al: Limited genetic susceptibility to severe
Graves' ophthalmopathy: No role for CTLA-4 but evidence for an
environmental etiology. Thyroid. 10:791–798. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ichimura M, Kaku H, Fukutani T, Koga H,
Mukai T, Miyake I, Yamada K, Koda Y and Hiromatsu Y: Associations
of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene
polymorphisms with susceptibility to Graves' disease in a Japanese
population. Thyroid. 18:625–630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hiromatsu Y, Fukutani T, Ichimura M, Mukai
T, Kaku H, Miyake I and Yamada K: Interleukin-12B gene polymorphism
does not confer susceptibility to Graves' ophthalmopathy in
Japanese population. Endocr J. 53:753–759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chong KK, Chiang SW, Wong GW, Tam PO, Ng
TK, Hu YJ, Yam GH, Lam DS and Pang CP: Association of CTLA-4 and
IL-13 gene polymorphisms with Graves' disease and ophthalmopathy in
Chinese children. Invest Ophthalmol Vis Sci. 49:2409–2415. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mukai T, Hiromatsu Y, Ichimura M, Fukutani
T, Kaku H, Miyake I, Shoji S, Koda Y and Bednarczuk T: Lack of
association of interleukin-18 gene polymorphisms with
susceptibility of Japanese populations to Graves' disease or
Graves' ophthalmopathy. Thyroid. 16:243–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han SZ, Zhang SH, Li R, Zhang WY and Li Y:
The common −318C/T polymorphism in the promoter region of CTLA4
gene is associated with reduced risk of ophthalmopathy in Chinese
Graves' patients. Int J Immunogenet. 33:281–287. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Q, Yang YM and Lv XY: Association of
Graves' disease and Graves' ophthalmopathy with the polymorphisms
in promoter and exon 1 of cytotoxic T lymphocyte associated
antigen-4 gene. J Zhejiang Univ Sci B. 7:887–891. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bednarczuk T, Hiromatsu Y, Fukutani T,
Jazdzewski K, Miskiewicz P, Osikowska M and Nauman J: Association
of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene
polymorphism and non-genetic factors with Graves' ophthalmopathy in
European and Japanese populations. Eur J Endocrinol. 148:13–18.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khalilzadeh O, Anvari M, Esteghamati A,
Mahmoudi M, Tahvildari M, Rashidi A, Khosravi F and Amirzargar A:
Graves' ophthalmopathy and gene polymorphisms in
interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and
interleukin-1 receptor antagonist. Clin Experiment Ophthalmol.
37:614–619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frosst P, Blom HJ, Milos R, Goyette P,
Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA,
van den Heuvel LP, et al: A candidate genetic risk factor for
vascular disease: A common mutation in methylenetetrahydrofolate
reductase. Nat Genet. 10:111–113. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Girelli D, Martinelli N, Pizzolo F, Friso
S, Olivieri O, Stranieri C, Trabetti E, Faccini G, Tinazzi E,
Pignatti PF and Corrocher R: The interaction between MTHFR 677
C->T genotype and folate status is a determinant of coronary
atherosclerosis risk. J Nutr. 133:1281–1285. 2003.PubMed/NCBI
|
|
29
|
Heijmans BT, Boer JM, Suchiman HE,
Cornelisse CJ, Westendorp RG, Kromhout D, Feskens EJ and Slagboom
PE: A common variant of the methylenetetrahydrofolate reductase
gene (1p36) is associated with an increased risk of cancer. Cancer
Res. 63:1249–1253. 2003.PubMed/NCBI
|
|
30
|
Kim NK, Choi YK, Kang MS, Choi DH, Cha SH,
An MO, Lee S, Jeung M, Ko JJ and Oh D: Influence of combined
methylenetetrahydrofolate reductase (MTHFR) and thymidylate
synthase enhancer region (TSER) polymorphisms to plasma
homocysteine levels in Korean patients with recurrent spontaneous
abortion. Thromb Res. 117:653–658. 2006. View Article : Google Scholar
|
|
31
|
Ko KH, Kim NK, Yim DJ, Hong SP, Park PW,
Rim KS, Kim S and Hwang SG: Polymorphisms of
5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and
thymidylate synthase enhancer region (TSER) as a risk factor of
cholangiocarcinoma in a Korean population. Anticancer Res.
26:4229–4233. 2006.
|
|
32
|
Ou CY, Stevenson RE, Brown VK, Schwartz
CE, Allen WP, Khoury MJ, Rozen R, Oakley GP Jr and Adams MJ Jr:
5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a
risk factor for neural tube defects. Am J Med Genet. 63:610–614.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sazci A, Ergul E, Tuncer N, Akpinar G and
Kara I: Methylenetetrahydrofolate reductase gene polymorphisms are
associated with ischemic and hemorrhagic stroke: Dual effect of
MTHFR polymorphisms C677T and A1298C. Brain Res Bull. 71:45–50.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin
Y, Wang X, Spitz MR and Wei Q: Polymorphisms of
5,10-methylenetetrahydrofolate reductase and risk of gastric cancer
in a Chinese population: A case-control study. Int J Cancer.
95:332–336. 2001. View Article : Google Scholar : PubMed/NCBI
|
